+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Maternal Mental Health Market - Global Maternal Mental Health Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2023-2030

  • PDF Icon

    Report

  • 270 Pages
  • September 2023
  • Region: Global
  • Fairfield Market Research
  • ID: 5887172

Global Maternal Mental Health Market Poised for Remarkable Growth, Projected to Reach US$40 Billion by 2030

The global maternal mental health market is on track to achieve a substantial valuation of US$40 billion by the close of 2030, driven by a robust compound annual growth rate (CAGR) of 28% during the period from 2023 to 2030. This unprecedented growth is attributed to several key factors, including increased government funding aimed at reducing maternal mortality, a surge in the incidence of postpartum depression, expanding awareness programs, and ongoing efforts to enhance practices related to maternal mental health.

Market Insights in Brief

The maternal mental health market's rapid expansion is underpinned by a combination of pivotal drivers, including positive reimbursement scenarios, a rising prevalence of postpartum depression (PPD), the implementation of widespread awareness initiatives, and the presence of a robust and reliable healthcare infrastructure.

Postpartum depression, a condition with significant implications for the mental well-being of postpartum mothers, commands the largest market share in the maternal mental health sector due to its widespread occurrence and profound impact.

Interpersonal therapy (IPT) has emerged as a leading therapeutic approach in the maternal mental health market, known for its effectiveness in addressing relationship-based stressors and enhancing maternal well-being during the perinatal period.

Regional Dynamics

North America remains at the forefront of the maternal mental health market, benefiting from enhanced accessibility to specialized care, counseling services, and support groups. The region's advanced healthcare infrastructure and proactive approach towards maternal mental health have contributed to its leadership position.

Asia Pacific, experiencing a surge in awareness about maternal mental health issues, is emerging as the fastest-growing market. The region's economic growth has led to improved healthcare infrastructure, increased access to medical facilities, and a growing emphasis on women's health.

Growth Drivers

Growing Government Funds Targeting Reduced Maternal Mortality

Government investments in mental health services and support for pregnant and postpartum women have played a pivotal role in reducing the risk of maternal mental health disorders. These funds have led to the expansion of maternal mental health services, including early detection, counseling, specialized clinics, and awareness campaigns, thereby reducing stigma and encouraging more women to seek help during pregnancy and postpartum periods.

Growing Incidences of Postpartum Depression

The rising prevalence of postpartum depression, coupled with improved screening and detection measures, has resulted in a higher demand for maternal mental health services. Timely intervention for postpartum depression is recognized as crucial to prevent long-term impacts on both mother and child well-being, further driving market growth.

Challenges

Mental Health Workforce Shortage

Despite the growing demand for mental health services during the perinatal period, a shortage of qualified experts remains a significant constraint. This scarcity leads to long wait times for appointments, limited access to specialized treatment, and delayed interventions, potentially affecting the health outcomes of pregnant and postpartum women.

Competitive Landscape

Key players in the maternal mental health market include Lipocine, Inc., Pfizer, Inc., Viatris, Inc., Bold Health, GlaxoSmithKline Inc., Alembic Pharmaceuticals Limited, Mallinckrodt, Inc., Sage Therapeutics, Inc., Bausch Health Companies Inc., and Magellan Health, Inc.

The global maternal mental health market's remarkable growth trajectory underscores its pivotal role in safeguarding the well-being of mothers and the health and development of their children. As governments, healthcare providers, and the private sector continue to invest in this critical healthcare segment, the market is poised to make substantial strides in the years ahead.


This product will be delivered within 1-3 business days.

Table of Contents

1. Executive Summary
1.1. Global Maternal Mental Health Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2022
1.5. Analyst Recommendations
2. Market Overview
2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter’s Five Forces Analysis
2.5. Covid-19 Impact Analysis
2.5.1. Supply
2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
2.7.1. World Economic Projections
2.8. PESTLE Analysis
3. Global Maternal Mental Health Market Outlook, 2018 - 2030
3.1. Global Maternal Mental Health Market Outlook, by Disease Indication, Value (US$ Bn), 2018 - 2030
3.1.1. Key Highlights
3.1.1.1. Postpartum Depression
3.1.1.2. Dysthymia
3.1.1.3. Pregnancy and Postpartum General Anxiety
3.1.1.4. Pregnancy and Postpartum OCD
3.1.1.5. Birth-Related PTSD
3.1.1.6. Others
3.2. Global Maternal Mental Health Market Outlook, by Therapy, Value (US$ Bn), 2018 - 2030
3.2.1. Key Highlights
3.2.1.1. Antidepressants
3.2.1.1.1. Selective serotonin reuptake inhibitors (SSRIs)
3.2.1.1.2. Tricyclic antidepressants (TCAs)
3.2.1.1.3. Other
3.2.1.2. Interpersonal Psychotherapy (IPT)
3.2.1.3. Cognitive Behavioural Therapy (CBT)
3.2.1.4. Other
3.3. Global Maternal Mental Health Market Outlook, by Region, Value (US$ Bn), 2018 - 2030
3.3.1. Key Highlights
3.3.1.1. North America
3.3.1.2. Europe
3.3.1.3. Asia Pacific
3.3.1.4. Latin America
3.3.1.5. Middle East & Africa
4. North America Maternal Mental Health Market Outlook, 2018 - 2030
4.1. North America Maternal Mental Health Market Outlook, by Disease Indication, Value (US$ Bn), 2018 - 2030
4.1.1. Key Highlights
4.1.1.1. Postpartum Depression
4.1.1.2. Dysthymia
4.1.1.3. Pregnancy and Postpartum General Anxiety
4.1.1.4. Pregnancy and Postpartum OCD
4.1.1.5. Birth-Related PTSD
4.1.1.6. Others
4.2. North America Maternal Mental Health Market Outlook, by Therapy, Value (US$ Bn), 2018 - 2030
4.2.1. Key Highlights
4.2.1.1. Antidepressants
4.2.1.1.1. Selective serotonin reuptake inhibitors (SSRIs)
4.2.1.1.2. Tricyclic antidepressants (TCAs)
4.2.1.1.3. Other
4.2.1.2. Interpersonal Psychotherapy (IPT)
4.2.1.3. Cognitive Behavioural Therapy (CBT)
4.2.1.4. Other
4.2.2. Market Attractiveness Analysis
4.3. North America Maternal Mental Health Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
4.3.1. Key Highlights
4.3.1.1. U.S. Maternal Mental Health Market by Disease Indication, Value (US$ Bn), 2018 - 2030
4.3.1.2. U.S. Maternal Mental Health Market by Therapy, Value (US$ Bn), 2018 - 2030
4.3.1.3. Canada Maternal Mental Health Market by Disease Indication, Value (US$ Bn), 2018 - 2030
4.3.1.4. Canada Maternal Mental Health Market by Therapy, Value (US$ Bn), 2018 - 2030
4.3.2. BPS Analysis/Market Attractiveness Analysis
5. Europe Maternal Mental Health Market Outlook, 2018 - 2030
5.1. Europe Maternal Mental Health Market Outlook, by Disease Indication, Value (US$ Bn), 2018 - 2030
5.1.1. Key Highlights
5.1.1.1. Postpartum Depression
5.1.1.2. Dysthymia
5.1.1.3. Pregnancy and Postpartum General Anxiety
5.1.1.4. Pregnancy and Postpartum OCD
5.1.1.5. Birth-Related PTSD
5.1.1.6. Others
5.2. Europe Maternal Mental Health Market Outlook, by Therapy, Value (US$ Bn), 2018 - 2030
5.2.1. Key Highlights
5.2.1.1. Antidepressants
5.2.1.1.1. Selective serotonin reuptake inhibitors (SSRIs)
5.2.1.1.2. Tricyclic antidepressants (TCAs)
5.2.1.1.3. Other
5.2.1.2. Interpersonal Psychotherapy (IPT)
5.2.1.3. Cognitive Behavioural Therapy (CBT)
5.2.1.4. Other
5.2.2. BPS Analysis/Market Attractiveness Analysis
5.3. Europe Maternal Mental Health Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
5.3.1. Key Highlights
5.3.1.1. Germany Maternal Mental Health Market by Disease Indication, Value (US$ Bn), 2018 - 2030
5.3.1.2. Germany Maternal Mental Health Market by Therapy, Value (US$ Bn), 2018 - 2030
5.3.1.3. U.K. Maternal Mental Health Market by Disease Indication, Value (US$ Bn), 2018 - 2030
5.3.1.4. U.K. Maternal Mental Health Market by Therapy, Value (US$ Bn), 2018 - 2030
5.3.1.5. France Maternal Mental Health Market By Disease Indication, Value (US$ Bn), 2018 - 2030
5.3.1.6. France Maternal Mental Health Market By Therapy, Value (US$ Bn), 2018 - 2030
5.3.1.7. Italy Maternal Mental Health Market By Disease Indication, Value (US$ Bn), 2018 - 2030
5.3.1.8. Italy Maternal Mental Health Market By Therapy, Value (US$ Bn), 2018 - 2030
5.3.1.9. Turkey Maternal Mental Health Market By Disease Indication, Value (US$ Bn), 2018 - 2030
5.3.1.10. Turkey Maternal Mental Health Market By Therapy, Value (US$ Bn), 2018 - 2030
5.3.1.11. Russia Maternal Mental Health Market By Disease Indication, Value (US$ Bn), 2018 - 2030
5.3.1.12. Russia Maternal Mental Health Market By Therapy, Value (US$ Bn), 2018 - 2030
5.3.1.13. Rest Of Europe Maternal Mental Health Market By Disease Indication, Value (US$ Bn), 2018 - 2030
5.3.1.14. Rest Of Europe Maternal Mental Health Market By Therapy, Value (US$ Bn), 2018 - 2030
5.3.2. BPS Analysis/Market Attractiveness Analysis
6. Asia Pacific Maternal Mental Health Market Outlook, 2018 - 2030
6.1. Asia Pacific Maternal Mental Health Market Outlook, by Disease Indication, Value (US$ Bn), 2018 - 2030
6.1.1. Key Highlights
6.1.1.1. Postpartum Depression
6.1.1.2. Dysthymia
6.1.1.3. Pregnancy and Postpartum General Anxiety
6.1.1.4. Pregnancy and Postpartum OCD
6.1.1.5. Birth-Related PTSD
6.1.1.6. Others
6.2. Asia Pacific Maternal Mental Health Market Outlook, by Therapy, Value (US$ Bn), 2018 - 2030
6.2.1. Key Highlights
6.2.1.1. Antidepressants
6.2.1.1.1. Selective serotonin reuptake inhibitors (SSRIs)
6.2.1.1.2. Tricyclic antidepressants (TCAs)
6.2.1.1.3. Other
6.2.1.2. Interpersonal Psychotherapy (IPT)
6.2.1.3. Cognitive Behavioural Therapy (CBT)
6.2.1.4. Other
6.2.2. BPS Analysis/Market Attractiveness Analysis
6.3. Asia Pacific Maternal Mental Health Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
6.3.1. Key Highlights
6.3.1.1. China Maternal Mental Health Market by Disease Indication, Value (US$ Bn), 2018 - 2030
6.3.1.2. China Maternal Mental Health Market by Therapy, Value (US$ Bn), 2018 - 2030
6.3.1.3. Japan Maternal Mental Health Market by Disease Indication, Value (US$ Bn), 2018 - 2030
6.3.1.4. Japan Maternal Mental Health Market by Therapy, Value (US$ Bn), 2018 - 2030
6.3.1.5. South Korea Maternal Mental Health Market by Disease Indication, Value (US$ Bn), 2018 - 2030
6.3.1.6. South Korea Maternal Mental Health Market by Therapy, Value (US$ Bn), 2018 - 2030
6.3.1.7. India Maternal Mental Health Market by Disease Indication, Value (US$ Bn), 2018 - 2030
6.3.1.8. India Maternal Mental Health Market by Therapy, Value (US$ Bn), 2018 - 2030
6.3.1.9. Southeast Asia Maternal Mental Health Market by Disease Indication, Value (US$ Bn), 2018 - 2030
6.3.1.10. Southeast Asia Maternal Mental Health Market by Therapy, Value (US$ Bn), 2018 - 2030
6.3.1.11. Rest of Asia Pacific Maternal Mental Health Market by Disease Indication, Value (US$ Bn), 2018 - 2030
6.3.1.12. Rest of Asia Pacific Maternal Mental Health Market by Therapy, Value (US$ Bn), 2018 - 2030
6.3.2. BPS Analysis/Market Attractiveness Analysis
7. Latin America Maternal Mental Health Market Outlook, 2018 - 2030
7.1. Latin America Maternal Mental Health Market Outlook, by Disease Indication, Value (US$ Bn), 2018 - 2030
7.1.1. Key Highlights
7.1.1.1. Postpartum Depression
7.1.1.2. Dysthymia
7.1.1.3. Pregnancy and Postpartum General Anxiety
7.1.1.4. Pregnancy and Postpartum OCD
7.1.1.5. Birth-Related PTSD
7.1.1.6. Others
7.2. Latin America Maternal Mental Health Market Outlook, by Therapy, Value (US$ Bn), 2018 - 2030
7.2.1. Key Highlights
7.2.1.1. Antidepressants
7.2.1.1.1. Selective serotonin reuptake inhibitors (SSRIs)
7.2.1.1.2. Tricyclic antidepressants (TCAs)
7.2.1.1.3. Other
7.2.1.2. Interpersonal Psychotherapy (IPT)
7.2.1.3. Cognitive Behavioural Therapy (CBT)
7.2.1.4. Other
7.2.2. BPS Analysis/Market Attractiveness Analysis
7.3. Latin America Maternal Mental Health Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
7.3.1. Key Highlights
7.3.1.1. Brazil Maternal Mental Health Market by Disease Indication, Value (US$ Bn), 2018 - 2030
7.3.1.2. Brazil Maternal Mental Health Market by Therapy, Value (US$ Bn), 2018 - 2030
7.3.1.3. Mexico Maternal Mental Health Market by Disease Indication, Value (US$ Bn), 2018 - 2030
7.3.1.4. Mexico Maternal Mental Health Market by Therapy, Value (US$ Bn), 2018 - 2030
7.3.1.5. Argentina Maternal Mental Health Market by Disease Indication, Value (US$ Bn), 2018 - 2030
7.3.1.6. Argentina Maternal Mental Health Market by Therapy, Value (US$ Bn), 2018 - 2030
7.3.1.7. Rest of Latin America Maternal Mental Health Market by Disease Indication, Value (US$ Bn), 2018 - 2030
7.3.1.8. Rest of Latin America Maternal Mental Health Market by Therapy, Value (US$ Bn), 2018 - 2030
7.3.2. BPS Analysis/Market Attractiveness Analysis
8. Middle East & Africa Maternal Mental Health Market Outlook, 2018 - 2030
8.1. Middle East & Africa Maternal Mental Health Market Outlook, by Disease Indication, Value (US$ Bn), 2018 - 2030
8.1.1. Key Highlights
8.1.1.1. Postpartum Depression
8.1.1.2. Dysthymia
8.1.1.3. Pregnancy and Postpartum General Anxiety
8.1.1.4. Pregnancy and Postpartum OCD
8.1.1.5. Birth-Related PTSD
8.1.1.6. Others
8.2. Middle East & Africa Maternal Mental Health Market Outlook, by Therapy, Value (US$ Bn), 2018 - 2030
8.2.1. Key Highlights
8.2.1.1. Antidepressants
8.2.1.1.1. Selective serotonin reuptake inhibitors (SSRIs)
8.2.1.1.2. Tricyclic antidepressants (TCAs)
8.2.1.1.3. Other
8.2.1.2. Interpersonal Psychotherapy (IPT)
8.2.1.3. Cognitive Behavioural Therapy (CBT)
8.2.1.4. Other
8.2.2. BPS Analysis/Market Attractiveness Analysis
8.3. Middle East & Africa Maternal Mental Health Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
8.3.1. Key Highlights
8.3.1.1. GCC Maternal Mental Health Market by Disease Indication, Value (US$ Bn), 2018 - 2030
8.3.1.2. GCC Maternal Mental Health Market by Therapy, Value (US$ Bn), 2018 - 2030
8.3.1.3. South Africa Maternal Mental Health Market by Disease Indication, Value (US$ Bn), 2018 - 2030
8.3.1.4. South Africa Maternal Mental Health Market by Therapy, Value (US$ Bn), 2018 - 2030
8.3.1.5. Egypt Maternal Mental Health Market by Disease Indication, Value (US$ Bn), 2018 - 2030
8.3.1.6. Egypt Maternal Mental Health Market by Therapy, Value (US$ Bn), 2018 - 2030
8.3.1.7. Nigeria Maternal Mental Health Market by Disease Indication, Value (US$ Bn), 2018 - 2030
8.3.1.8. Nigeria Maternal Mental Health Market by Therapy, Value (US$ Bn), 2018 - 2030
8.3.1.9. Rest of Middle East & Africa Maternal Mental Health Market by Disease Indication, Value (US$ Bn), 2018 - 2030
8.3.1.10. Rest of Middle East & Africa Maternal Mental Health Market by Therapy, Value (US$ Bn), 2018 - 2030
8.3.2. BPS Analysis/Market Attractiveness Analysis
9. Competitive Landscape
9.1. Disease Indication vs Application Heatmap
9.2. Manufacturer vs Application Heatmap
9.3. Company Market Share Analysis, 2022
9.4. Competitive Dashboard
9.5. Company Profiles
9.5.1. Pfizer, Inc.
9.5.1.1. Company Overview
9.5.1.2. Product Portfolio
9.5.1.3. Financial Overview
9.5.1.4. Business Strategies and Development
9.5.2. Lipocine, Inc.
9.5.2.1. Company Overview
9.5.2.2. Product Portfolio
9.5.2.3. Financial Overview
9.5.2.4. Business Strategies and Development
9.5.3. Viatris Inc.
9.5.3.1. Company Overview
9.5.3.2. Product Portfolio
9.5.3.3. Financial Overview
9.5.3.4. Business Strategies and Development
9.5.4. GlaxoSmithKline plc
9.5.4.1. Company Overview
9.5.4.2. Product Portfolio
9.5.4.3. Financial Overview
9.5.4.4. Business Strategies and Development
9.5.5. Alembic Pharmaceuticals Limited
9.5.5.1. Company Overview
9.5.5.2. Product Portfolio
9.5.5.3. Financial Overview
9.5.5.4. Business Strategies and Development
9.5.6. Mallinckrodt, Inc.
9.5.6.1. Company Overview
9.5.6.2. Product Portfolio
9.5.6.3. Financial Overview
9.5.6.4. Business Strategies and Development
9.5.7. Sage Therapeutics, Inc.
9.5.7.1. Company Overview
9.5.7.2. Product Portfolio
9.5.7.3. Financial Overview
9.5.7.4. Business Strategies and Development
9.5.8. Bold Health
9.5.8.1. Company Overview
9.5.8.2. Product Portfolio
9.5.8.3. Financial Overview
9.5.8.4. Business Strategies and Development
9.5.9. Bausch Health Companies Inc.
9.5.9.1. Company Overview
9.5.9.2. Product Portfolio
9.5.9.3. Financial Overview
9.5.9.4. Business Strategies and Development
9.5.10. Magellan Health, Inc.
9.5.10.1. Company Overview
9.5.10.2. Product Portfolio
9.5.10.3. Financial Overview
9.5.10.4. Business Strategies and Development
10. Appendix
10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Lipocine, Inc.
  • Pfizer, Inc.
  • Viatris, Inc.
  • Bold Health
  • GlaxoSmithKline plc
  • Alembic Pharmaceuticals Limited
  • Mallinckrodt
  • Sage Therapeutics, Inc.
  • Bausch Health Companies, Inc.
  • Magellan Health, Inc.

Methodology

Loading
LOADING...